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by 
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Abstract 
The paper provides an overview of the types of economic costs, benefits, and risks involved 
with agricultural biotechnology at the farm level, at the market level, and for the farm and food 
system as a whole. Both advantages and disadvantages of agricultural biotechnology are 
discussed. Among the drivers of the US. domestic and international consumer demand for 
transgenic crop products discussed in the paper are environmental and food safety concerns. A 
comparison is made between a 'science-based' regulatory framework and a policy based on the 
precautionary principle. The authors argue that open dialogue is needed for achieving improved 
public understanding of agricultural biotechnology, and that analyses need to go beyond 
discussing the scientific merits of biotechnology, to include social scientists, as well as the public 
at large. 
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Selected Economic Implications and Policy Aspects of Agricultural Biotechnology 
Background 
Biotechnology involves making changes to the cellular and molecular structure of organisms. 
The application of biotechnology by way of genetic modification and selection to increase 
agricultural productivity is as old as agriculture itself. What makes modem genetic 
engineering-as a form of biotechnology-different from traditional means of manipulating the 
biology of plants and animals is that it enables individuals to move functional genes from one 
organism to another. In this paper, the term 'biotechnology' refers to the technique used by 
biological scientists to modify genes within an organism or to transfer specific genes between 
organisms. Thus, genetic engineering facilitates the development of characteristics that are not 
possible through traditional breeding techniques. In this paper, the terms "biotechnology," 
"bioengineering," and "genetic engineering" are used interchangeably, and refer to the use of 
modem genetic techniques to obtain "genetically modified" or "transgenic" plants and animals. 
This paper provides an overview of selected economic issues and policy choices involved 
with agricultural biotechnology. It is not meant to provide a comprehensive review of all 
economic issues involved with this new technology. Instead, the paper's focus is on the 
economic costs, benefits, and risks that are associated with the use of agricultural biotechnology 
within a farm and food system driven by domestic and international consumer demand. The 
paper also provides an analysis of how agricultural production, consumer demand, and rural 
areas are potentially affected by policy choices associated with the use of agricultural 
biotechnology. 
The next section provides an overview of some of the major controversies associated with 
agricultural biotechnology. This is followed by an analysis of the pros and cons of the use of 
biotechnology, described in general, as well as from the perspectives of agricultural producers 
and agricultural markets. This is followed by a description of consumer concerns and 
international trade issues. A separate section is devoted to the 'precautionary principle.' 
The Three Phases of Biotechnology 
Genetically engineered crops are generally classified into two, or sometimes three, 
generations or "waves" (Fernandez-Cornejo, et al.; and Hillier). The current set of genetically 
engineered products is limited primarily to agronomic input traits that have not provided-and 
were not intended to give-significant benefits beyond conventional agricultural products to 
consumers. An example of a trait developed with the use of biotechnology is decreased pest 
susceptibility, which reduces the need for chemicals that prevent plant diseases and insect 
infestations. Other production-level traits currently being developed using genetic engineering 
are the ability of plants to grow under saline conditions, to increase their tolerance to frost, and 
to improve their ability to resist drought. Further, Federal approval is currently being sought to 
market genetically engineered Atlantic salmon that grow to market size in half the time as 
normal Atlantic salmon (Yoon, 2000a). 
A second set of products, many of which have already been developed but are awaiting 
approval for marketing, is characterized by output traits that enhance the products' processing 
characteristics and that have improved quality characteristics for consumption purposes. This 
second generation of biotechnology products includes, for example, fats and starches with 
improved processing and digestibility characteristics. Other examples of second wave products 
are provided by Coaldrake; and Shoemaker (p. 19). 
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Fernandez-Cornejo et al. identify a third generation of biotechnology products, with an 
emphasis on end user quality traits. These products include nutraceuticals or functional foods, 
which may be produced using crops engineered to contain medicines or food supplements within 
plants. 
Most of the current applications in agricultural biotechnology are still in the first generation 
of genetically engineered products. Nevertheless, innovations by way of biotechnology already 
appear to be on their way to becoming one of the most rapidly adopted types of technology in 
agricultural history. 
How Widespread is Biotechnology in Agricultural Production? 
Because of the very rapid growth in the use of various applications of agricultural 
biotechnology in crop production, few reliable estimates of global cropland used for genetically 
engineered field crops are available. Further, the reliability of existing data on the use of 
agricultural biotechnology is somewhat questionable for some nations because of the 
controversial nature and property rights issues involved with agricultural biotechnology. For 
example, Brazil does not allow the planting of genetically modified soybeans, but its fam1ers are 
widely thought to grow such soybeans. 
Virtually all studies that list data on the global spread of genetically engineered crops are 
based on one source, the International Service for the Acquisition of Agri-biotechnology 
(ISAAA), cited as "James." The ISAAA is a publicly and privately funded organization and has 
an international network that consists of several centers, one of which is affiliated with Cornell 
University. 
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Based on the data collected by James, global cropland planted with bioengineered crops 
increased from four million acres when the crops became commercially available in 1996, to an 
estimated 109 million acres in 2000, spr�ad over 12 countries (see Table 1 ). The United States 
and Canada account for more than three-fourths of global cropland acres grown with genetically 
engineered crops. Many of the remaining cropland acres used for transgenic crops are located in 
Argentina. Other major producers of agricultural products, such as Brazil and China, are also 
expected to become major participants in growing transgenic crops (Smith). Nations that also 
grow transgenic crops but are not listed in this table include Romania, Mexico, Bulgaria, Spain, 
Germany, France, and Uruguay. 
Table 2 lists the number of cropland acres devoted to genetically engineered crops. The table 
shows that in 2000, soybeans accounted for approximately 58 percent of the world's cropland 
acres used for genetically engineered crops, followed by com with about 23 percent, cotton with 
approximately 12 percent, and canola with about seven percent of the global cropland area used 
for transgenic crops. 
Globally, as well as in the United States, the area planted to genetically engineered crops 
leveled off somewhat between 1999 and 2000. Table 2 shows that cropland areas planted with 
transgenic soybeans and cotton increased from their 1999 levels, while the planted areas of 
genetically engineered com and canola underwent a slight decrease from their 1999 levels. 
Agriculture in the Upper Midwest has been in the forefront of biotechnological advances, 
and some of the most controversial biotechnology products are produced in the region. Tables 3 
through 5 list the extent to which transgenic com, soybean, and upland cotton varieties, 
respectively, were planted in the United States and in selected states in 2001. Approximately 26 
percent of the nation's com area, 68 percent of the soybean area, and 69 percent of the cotton 
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area was planted with bioengineered crops in 2001. Among 1 1  Midwestern states, South Dakota 
ranked first in the percentage of total cropland planted with genetically modified com, and the 
state shared its number one position with Kansas in the percentage of total cropland planted with 
transgenic soybeans in 2001 (U.S. Department of Agriculture). 
Globally, the most important genetically engineered trait used in crops is herbicide 
resistance, which accounted for 69 percent of the total global cropland area planted with 
transgenic crops in 1999 (see Table 6). In the same year, insect-resistant crops accounted for 
about 21  percent of the world's cropland area sown with transgenic crops. Crops containing both 
herbicide-resistant and insect-resistant genes accounted for about seven percent of global 
cropland area planted with transgenic crops. Finally, virus-resistant transgenic crops comprised 
close to three percent of the world's cropland acres sown with transgenic crops (James). 
Controversies 
From its beginnings, the use of biotechnology in agriculture has been controversial. 
Independent evidence on the benefits and costs of most agricultural biotechnologies is limited, 
and most of the technology's effects on the environment, food safety, and industry structure 
remain unknown at this early stage. While some agricultural biotechnology applications have 
been adopted widely and at a very rapid pace, their number remains very limited, and all 
technologies were implemented relatively recently. As a result, there has been little opportunity 
to observe impacts over an extended period of time and over a wide variety of climatic 
conditions. Also, public funding for research on the potential impacts and risks of agricultural 
biotechnology has been very limited. Nevertheless, excellent reviews of the currently available 
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evidence on potential benefits, costs, and risks of various biotechnologies have been provided by 
Ervin, et al.; and Pretty (1999; and 2000), among others. 
Benefits 
Supporters of the use of biotechnology in agriculture argue that it will improve global and 
local food security by helping developing nations provide food for their own citizens 
(McGloughlin). This would be achieved by increasing agricultural output per unit of land and by 
decreasing production variability. Also, the technology might allow for an increase in 
agricultural productivity relative to non-land inputs and a decrease in production costs. This 
could include, for example, an increase in crop yield per unit of fossil fuel energy inputs or per 
unit of chemical pesticide inputs. Furthermore, proponents argue that applications of agricultural 
biotechnology are necessary to meet a rapidly expanding global demand for food. 
Advocates also argue that biotechnology improves the environment by reducing the need for 
chemicals in agricultural production. The reduced use of pesticides and herbicides, in tum, 
would reduce human health hazards associated with the use of these chemicals. Finally, the 
technology is expected to yield a variety of new or enhanced 'quality' characteristics, such as 
protein or sugar contents. 
Costs 
The potential benefits associated with particular biotechnologies may be accompanied with 
new or additional costs accruing to adopters and others in the farm and food system, but also to 
other individuals and groups. For example, the use of herbicide tolerant crop varieties involves 
higher seed costs and may sometimes result in lower per acre yields, relative to using 
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conventional varieties. At the farm level, those costs must be weighed against potentially lower 
labor, machinery, and chemical pesticide costs in determining the net impact on farm 
profitability. 
Farther up the supply chain, some agribusinesses involved in grain handling are likely to 
experience increased costs associated with segregating genetically modified grains from those 
produced using traditional technology if consumer resistance to products containing genetically 
modified products or processes continues in major foreign markets. Those costs may or may not 
be offset by premiums that handlers can capture or by charges that they are able to assess. 
From an economic perspective, technological change is, in principle, viewed 
favorably--because it frees up scarce resources for use elsewhere. There are two types of 
technological change: cost-reducing and quality-enhancing (Caswell, Fuglie, and Klotz). A cost­
reducing change lowers input costs, enabling increased input usage and increased crop yields. 
Cost-reducing changes generally cause an increase in the aggregate supply of a product. Further, 
a cost-reducing change is likely to have broad appeal, because many producers would be willing 
to adopt the technology. For example, if the cost of producing com decreases, farmers have an 
incentive to increase their production. The resulting increase in the aggregate supply of com 
would likely result in lower com prices. 
Biotechnology also may result in quality-enhancing changes to the underlying commodity. 
By improving product quality, new or improved uses for the commodity become possible. This 
would cause a shift in the demand for the product, and may lead to higher prices. However, the 
appeal of quality-enhanced crops may be limited to specific sectors, such as the market for high­
oil com. 
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A thorough analysis of the impacts of agricultural biotechnology on the farming and food 
system must include 'technological' (or physical) externalities, as opposed to 'pecuniary' (or 
price effect) externalities. An example of a technological external cost would be pollen drift 
from transgenic crops 'contaminating' a neighbor's organic crop. Crops grown with genetically 
modified seed stock do not qualify for organic certification, and would therefore forego organic 
price premiums. Consequently, this type of seed stock contamination can have severely adverse 
economic ramifications for organic farmers, who are unwilling recipients of the impacts of 
agricultural biotechnology adoption decisions by others. 
Risks 
A system-wide economic analysis on the impacts of agricultural biotechnology not only 
includes an investigation of benefits and costs, but also incorporates risks associated with the 
new technology. Risks in a systems analysis of genetically modified technologies generally are 
those potential costs that, at best, we can only estimate in rough, probabilistic terms. Often 
included here are health or food safety and environmental risks (Feldmann, et al.; and 
Fernandez-Cornejo, et al.). A health concern associated with agricultural biotechnology is that 
persons with allergies may suffer reactions to genetically modified foods, when allergenic 
substances are inadvertently transferred from one food product to another. In response to 
concerns among their citizens about the safety of using biotechnological processes, a number of 
European countries have banned the importation of many bioengineered products. Thus far, U.S. 
domestic consumers have been less concerned about the side effects of genetically engineered 
foods than some of their European, Japanese, and South Korean counterparts. 
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Among the environmental risks that have been raised is the concern referred to as the 'super 
weed' problem, caused by genetic drift to wild relatives of the target species that develop into 
weeds. A second concern is that new genes may move to wild and unrelated plants, which could 
then become weeds. Third, the use of the technology may harm non-target species, such as 
butterflies that depend upon the target species' ecosystem. A fourth risk associated with using 
biotechnology is that new viral pathogens and pathogenic bacteria may be introduced to the 
environment. A additional environmental fear is that the genetic trait in the target species may 
decline in efficacy over time. For example, pesticide resistance may develop from increased 
Bacillus Thuringiensis (Bt) toxins use, necessitating the use of higher dosages of, or more toxic, 
chemical pesticides later. Finally, bioengineered species may have broad environmental impacts 
by disrupting the natural evolution of valuable species and decreasing their productivity or by 
causing a proliferation of new genetically modified species that crowd out others. 
Of direct concern to those in production agriculture is that biotechnology is certain to affect 
the structure of agriculture. Since the introduction of biotechnology in the mid-1990s, its rapid 
spread in production agriculture already appears to have sped up ongoing structural changes 
taking place in agriculture. The technology enables agricultural input industries, such as seed 
companies, to increase their control over plant production, mitigating agricultural producers' 
ability to reuse seeds, and leading to reduced control among farmers over their production 
processes. Both cost reducing and quality-enhancing types of technology changes may impact 
the structure of agriculture. The extent to which biotechnology affects the number and size of 
farms depends on the 'economies of size' related to adopting the technology. To date, many 
innovations due to agricultural biotechnology have been scale-neutral (Caswell, Fuglie, and 
Klotz). That is, they tend to impact only variable costs of production, such as those involved 
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with seed and pesticide purchases. However, if new technologies require large fixed costs to 
adopt, they may favor larger farms. 
Analyzing Costs, Benefits, and Risks 
In an attempt to put the benefits, costs, and risks associated with biotechnology in 
perspective, Young has devised a set of three principles for analyzing new technologies in 
general. The first principle is the realization that both proponents and opponents of 
biotechnology strive toward the same goal, which is the responsible use of the new technology. 
Insufficient attempts have been made among groups and individuals for and against the use of 
biotechnology-whether in corporate, academic, and government environments-to acknowledge 
this fundamental factor. Without this realization, progress in a constructive dialogue among 
groups and individuals with varying views regarding the extent to which biotechnology should 
be used in the food and fiber sector will be limited. 
The second principle is that there are valid concerns about, and potential valid benefits from, 
the impacts of biotechnology. While biotechnology may become an effective tool to alleviate 
world hunger, it is generally recognized among scientists that pollen transfer to non-targeted 
crops will occur. Scientists also recognize that insect resistance to Bt toxins is likely to develop, 
because target insects are continually exposed to the toxins, creating strong selection pressures 
for developing resistance to these toxins. Acknowledging both benefits and shortcomings of the 
technology will improve the transparency of the discussion. 
The third principle is that the evaluation of biotechnology and its uses should be based on 
generally accepted principles that currently exist in the various sciences for conducting 
comprehensive system-wide analyses. 
10 
An additional principle that may be added is that both proponents and opponents of 
biotechnologies should attempt to avoid sensationalism and exaggaration in discussing 
advantages and disadvantages of the technology. That is, neither the benefits nor the concerns 
should be overstated. A case in point is "Golden Rice," which was engineered to contain three 
new genes that together cause rice to produce beta carotene, a precursor of vitamin A. The 
genetically engineered rice was intended to prevent vitamin A deficiency, a common cause of 
childhood blindness in developing countries. However, because beta-carotene must be split by an 
enzyme to become active, and because both beta-carotene and vitamin A are soluble in fat 
only-requiring a balanced diet containing a sufficient amount of fats and nutrients-Golden Rice 
alone does not have the ability to eliminate vitamin A deficiency. 
At a more practical level, we can use Bt com to illustrate the possible distribution of selected 
benefits, costs, and risks among different stakeholders in society. The entries in the cells of 
Figure 1 include some of the possible impacts on different groups of people, including people in 
other countries. Potential benefits of Bt com include reduced production costs for farmers and 
increased profits for companies producing and selling the Bt seed. There may also be the 
environmental benefit of reduced chemical pesticide use, although evidence of reduced pesticide 
use resulting from the growth in Bt com area is mixed (Ervin, et al.; and Pretty, 2000). Further, 
whether any chemical use reductions are lasting will depend in part on how soon resistance to 
the Bt toxin builds up. 
Among the costs associated with the _genetically engineered com are those involved with 
segregating genetically modified from traditionally produced com and its products. These costs 
would be faced by both farmers and agribusinesses if a significant portion of the com market 
exhibits demand for products free of genetically modified products. In addition, farmers in 
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countries where genetically modified com is not widely adopted ( countries referred to as the 
'Rest of the World,') could face increased competition from lower-cost U.S. imports, if allowed. 
Environmentally, the Bt technology probably makes it easier for farmers to continue 
specializing in the rather narrow com-soybean rotation. A growing number of people feel that 
this continued lack of crop biodiversity is unsound from an ecological sustainability standpoint. 
Further, the StarLink® com incident suggests that public agencies meaning US 
taxpayers-potentially face increased costs in dealing with regulations and consequences 
associated with agricultural biotechnology. In the StarLink® case, the U.S. Department of 
Agriculture agreed to spend $20 million to purchase seed from small companies that find their 
seed supplies 'contaminated' with the Cry9C gene. Finally, the increased concentration 
occurring in the agricultural input industry as genetically modified technologies take on greater 
importance could adversely affect rural areas, as could the continued increase in farm size and 
decrease in farm numbers that tend to accompany technologies which facilitate narrow crop 
systems. 
Among the alleged risks of Bt com technology are possible health risks. For example, while 
StarLink® com has not been shown to pose a health risk, neither was it approved for human 
consumption; it entered into the human food system in spite of regulations prohibiting that. 
Similarly, consumers in the 'Rest of the World' countries feel that they also face risks of Bt com 
finding its way into their food systems without their knowledge, in spite of various regulations 
and labeling practices designed to guard against that in much of Europe. 
Another risk is that widespread use of Bt crops may result in resistance to the natural Bt 
spray that is approved for use in organic production, thereby rendering useless or less useful one 
of the pest control tools used by some organic fruit and vegetable producers. Also, although 
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evidence available thus far is mixed, there is concern that Bt com may be toxic to some 
butterflies and beneficial insects (Ervin, et al.). 
This illustration of how different groups throughout society may be either beneficially or 
adversely affected by agricultural biotechnology shows why we should not be surprised by the 
controversies currently surrounding public policies regarding the application of this new 
technology in producing food and fiber. The controversies are not simply because of an 
' uninformed public' or 'distortions in the media.' At least in the short run, genetically modified 
technologies will have potential real gainers and losers. 
From a research policy perspective, it is not only important that the costs, benefits, and risks 
of biotechnology are compared, but also that the resulting net gain or loss from implementing 
agricultural biotechnology be weighed against alternative, appropriate, and locally feasible 
technologies. Ruttan argues that many developing nations have not yet realized potential yield 
gains from conventional crop improvement efforts because of a lack of research and 
development capacity. Improved knowledge in agronomic practices may also contribute to rapid 
yield increase, as illustrated in a New York Times article, which reported that a mixture of two 
different rice varieties doubled rice production without additional chemical inputs (Yoon, 
2000b ). Finally, and perhaps most importantly, no amount of change in technology in 
agricultural production will relieve world hunger without accompanying political reforms that 
facilitate group and individual access to food. 
Agricultural Producer Considerations 
Costs and benefits associated with adopting biotechnology in agriculture are not only 
important from a policy perspective, but also for individuals interested in applying the new 
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technology. Similar to other participants in the food and fiber system, agricultural producers 
respond to economic incentives and will produce those products that provide them with the 
greatest expected returns. In the case of crops, those produced using biotechnology are different 
from crops produced without this new technology, because the new crops have traits that are 
dissimilar from those of conventionally produced crops. Hence, crop producers would be prudent 
to consider currently existing genetically modified crops as products with value-enhanced traits 
and not treat them as commodities. Producers should also manage the genetically modified crops 
differently than agricultural commodities. 
In considering whether or not to switch from growing conventional to growing genetically 
modified crops, producers need to understand costs and benefits associated with growing the 
new crops. This could be achieved by conducting a marginal analysis for a crop, which entails 
making a comparison between the net revenue per acre from producing and marketing the new 
crop, and the net revenue of a conventional commodity. The expected gross revenue obtained 
from growing and marketing the modified crop would include a price premium or discount, 
multiplied by the yield (accounting for any yield drag). On the cost of production side, 
technology fees would need to be added and now unnecessary inputs would need to be 
subtracted. If the net revenue associated with producing the crop that utilizes the new technology 
would exceed that of a traditionally produced commodity, an incentive to change to producing 
the genetically modified crop exists. 
Marginal analysis provides an initial assessment of whether or not switching to genetically 
engineered crops is financially worth considering for crop producers, but it may need to be 
supplemented with other considerations. First, producers do not need to adopt new technologies 
if they do not want to. Second, blindly adopting the new technology may create previously 
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nonexistent operating problems. Third, some crop traits have changed the underlying commodity 
sufficiently to cause a change in its crop insurance treatment. This is clearly the case in the 
presence of any yield drag that affects the crop insurance premium. Fourth, producers who 
consider contracting their crop must identify alternative markets for obtaining the crop before 
finalizing their contract, in case of a harvest shortfall and subsequent inability to meet contract 
obligations. Fifth, a genetically modified crop that does not meet the delivery specifications 
committed to in futures or cash forward contracts may generate price risk management 
difficulties for producers. Even if the crop would be acceptable to buyers, its value may not 
fluctuate consistently with commodity prices, resulting in additional basis risks and reduced 
hedging effectiveness. Fina11y, local production and marketing systems may also affect 
producers ' decisions whether to adopt genetically modified crops. For example, if local elevators 
do not have handling facilities for keeping transgenic crops separate from conventional crops, 
farmers would need to find alternative distribution channels, resulting in additional costs. 
A Market Perspective 
Many decision makers in the grain production and marketing system see biotechnology as 
both a threat and an opportunity. On the one hand, the rapid introduction of new technologies has 
the potential to disrupt normal planting and merchandising patterns. On the other hand, 
technological advances are not new or unusual, and the mechanisms for understanding their 
impacts are available. Different types of technological changes affect prices in different ways. 
Also, whether a new product represents a valuable segment of the market or a costly segregation 
within the market also depends on the type of technology introduced. The market has had some 
time to adapt to biotechnology and has started sending signals to market participants with 
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estimates of market sizes and price premiums or discounts for the various products. These 
signals will ultimately drive the production system, because planting decisions by farmers, 
marketing decisions by grain handlers, and the product choice of processors are ultimately 
driven by profitability criteria. 
Segmentation 
A market is said to be segmented when a variety of products of a similar type have 
distinguishing characteristics that give individual products a different value to consumers. 
Biotechnology is one avenue for segmenting the market for crops that are generally regarded as 
commodities (com from Iowa is the same as com from South Dakota). The objective of adding a 
value-enhanced trait- that is, a characteristic desired by consumers-is to segment the com market 
and make the value-enhanced com worth more than commodity com. 
For centuries, mother nature has received the credit for improvements in the quality 
characteristics of plants using traditionar plant breeding methods, although producers have 
traditionally captured the entire premium involved with plant quality enhancement. When crops 
with value-enhanced traits are developed, developers and producers share the premium, usually 
through a technology fee. Regardless of the source of the trait, its additional value needs to be 
communicated to consumers for it to be captured by producers. The distinguishing feature of 
crops with value-enhanced traits is that the trait is anticipated by agricultural producers and is 
expected to have additional value. Thus, when a value-enhanced trait is introduced, producers 
anticipate capturing potential premiums, although the premiums may have to be shared with 
other participants in the marketing system, because it may cost more to keep the value-enhanced 
crop segmented than if  it were simply a commodity. If, however, producers were to seek to 
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capture the entire premium themselves, they would also be expected to build up the entire supply 
chain, involving direct marketing of farm products to consumers. The existing marketing system 
may also handle the trait, for example through a protein premium. Identity preserved crops are 
another way the marketing system handles such traits, but at a cost. 
Segregation 
Vv'hile segmentation is seen as positive, a negative trait may result in the need for 
segregation. In this case, a trait causes the product to fail to meet either the standard commodity 
specifications or other regulatory specifications. Such traits impose a cost to the marketing 
system and cause producers to face a discount for the trait. Because these negative traits tend to 
surprise the marketing system, they are more costly to deal with than anticipated traits. Hence, 
discounts for such traits may be disproportionate to premiums observed for quality-enhanced 
traits. 
The marketing system has some experience handling negative traits. For example, in some 
locations in South Dakota, wheat with a low protein content was discounted in price in recent 
years. Another example is provided by the presence of vomitoxin in wheat, which led to large 
price discounts and segregation costs in South Dakota and neighboring states. Further, the 
distribution problems associated with the StarLink® controversy is but the latest example. The 
extent of the discounts depends on the relative supply of the crop with the negative trait and the 
demand for products produced in the segmented market. 
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Market Structure and Conduct 
What is the size of the various markets today? How are the production and marketing 
systems responding to segmented and segregated markets? A look at the market structure reveals 
that while the market for crops using traditional production methods is real, it may not be very 
large. Researchers of the Economic Research Service have offered estimates about the size of the 
non-biotechnology com and soybean markets (Lin, Chambers, and Harwood). They suggest that 
the markets for non-biotechnology com and soybeans were about one and two percent, 
respectively, of U.S .  com and soybean production in 1 999. They also point out that the market 
for non-transgenic com by-products is unknown, but likely depends largely on demand from the 
European Union. 
Lin, et al. also report that 1 5  percent of farmers are considering ways to handle their own 
crops in segmented form in an effort to capture premiums and/or avoid discounts. About five 
percent of the nation' s elevators are pre-equipped to adequately handle genetically modified and 
non-genetically modified crops simultaneously. River elevators may have a comparative 
advantage, because they tend to be larger and handle grain differently than do country elevators. 
Imposed segregation of genetically modified crops would have a large cost, estimated at 22 cents 
per bushel for corn and 54 cents per bushel for soybeans. 
The premiums for non-genetically modified corn and soybeans have rarely been large 
enough to match the cost of segregation. Non-genetically modified corn has typically garnered 
five to ten cents per bushel in premiums, while non-genetically modified soybeans have received 
ten to 1 5  cents per bushel above commodity values (Lin, et al.) .  Recent data from the U.S .  
Department of  Agriculture show premiums of seven to 12 cents for non-genetically modified 
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corn and 20 to 25 cents for non-genetically modified soybeans. Further information on market 
size and prices of value-enhanced grains is provided by the U.S. Grains Council. 
Consumer Concerns and International Trade 
Agricultural commodities produced with the use of biotechnology are at the center of 
ongoing trade negotiations and discussions with major U.S. trading partners. Import restrictions 
and labeling requirements of transgenic products are expected to be major agenda items in the 
next round of World Trade Organization (WTO) negotiations. International trade of genetically 
engineered products-primarily for use in agriculture-is governed by the "Cartagena Protocol on 
Biosafety," adopted in Montreal, Canada, on January 29, 2000. This protocol was negotiated 
under the United Nations Convention on Biological Diversity. A number of nations have 
regulatory agencies in place to oversee national biotechnology endeavors. However, with the 
exception of the European Union, there are few other international regulations for genetically 
engineered products. The Cartagena Protocol is one of the first legally binding international 
agreements to govern the products of biotechnology, and it is the first to require consent of an 
importing country prior to trading genetically engineered products. The protocol also allows for 
an assessment of potential risks to biodiversity and human health in the importing country 
associated with transferring these products. 
The negotiations that led to the protocol evolved from an increased awareness and public 
concern about environmental and food safety issues, to an escalating trade conflict between the 
United States and the European Union (EU) involving genetically engineered products. 
Particular concerns were raised among European nations, but Japan and South Korea also 
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imposed trade restrictions in response to their domestic consumers' concerns about agricultural 
biotechnology. 
In contrast, the majority of U.S. consumers and the U.S. public at large have long held a high 
degree of confidence in the reliability of their food and fiber system's regulatory processes, in 
part because of ample and presumably safe food supplies. One of the reasons often cited for EU 
residents' suspicious attitudes towards genetically engineered food products is that there have 
been a series of well-publicized cases that jeopardized the safety of the EU food supply. For 
example, food safety concerns developed in response to the Bovine Spongiforrn Encephalopathy 
(BSE) or mad cow disease case that started in the United Kingdom in the 1980s and 
subsequently spread to mainland Europe. Other food safety concerns were raised elsewhere in 
Europe after a series of toxins were found to have entered the food chain or water supplies in the 
late 1990s. Perhaps more important than finding the food contaminants themselves was the fact 
that in each case, government officials attempted to reassure consumers about the safety of the 
food supply, only to be proven wrong later. More importantly, most European nations have 
historically not had central regulatory agencies that would oversee the safety of the food supply, 
or equivalents to the U.S. Food and Drug Administration. As a consequence, many European 
nations were left to regulate and impose restrictions on final products, rather than the process in 
which the product is produced-the approach used in the United States. 
The European experience suggests that a major challenge in today's environment in which 
the development of agricultural biotechnology is taking place in the United States is to maintain 
public and consumer confidence in the regulatory and research systems. It is likely that U.S. 
confidence in the regulatory system also would decline if similar events to those in Europe were 
to occur. While the StarLink® case may .have been "an accident waiting to happen," it does 
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indicate system weaknesses that need to be addressed, because the U.S. agricultural system 
traditionally has not made a distinction between two seemingly identical raw agricultural 
products that were destined for separate food and feed markets. 
Even without further mishaps in the way that agricultural biotechnology is incorporated in 
the food and fiber system, genetically engineered products have characteristics that have the 
potential to raise concerns among consumers. Prior to the development of modem 
biotechnology, Lowrance (p. 87), developed general characteristics of products that tend to 
increase the perception of danger among· consumers. These characteristics were further 
developed by Senauer, et al. (p. 250). Consumers perceive a general increase in the risks 
associated with products: (1) whose risks are unknown, (2) that have irreversible consequences 
(3) which exposed them involuntarily to the risks (4) if there are many alternatives available, and 
(5) that are not needed by consumers. Each of these five characteristics, as well as others, can be 
applied to genetically engineered products as they relate to consumers in the European Union, 
Japan, the United States, and other wealthy nations. Therefore, it is hardly surprising that 
concerns exist among individuals in some of these nations. Further, dismissing the current 
controversies about genetic modification technologies in agriculture as being largely due to an 
uninformed public and distortions in the media, is based on false premises. A technology with 
such profoundly new and different elements as genetic modification has many unknown 
consequences. Inevitably, some individuals and groups will benefit from the technology, while 
others will be negatively impacted. One need only consider the history of the Industrial 
Revolution for that to be abundantly apparent. Furthermore, different individuals and cultures 
vary in their 'values, ' especially as they weigh the importance of potential benefits of a new 
technology in relation to that technology's perceived costs and risks. 
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The 'Precautionary Principle ' 
Democratic governments differ in the way they decide about which genetically modified 
products should be approved for commercial application-given the potential benefits, costs, and 
risks for different segments of society. U.S. policies are based primarily on a so-called 'science-
based' approach, in which approval for commercial application is ultimately given if there is no 
proof of harm. This approach is based on the American philosophy which tends to view science 
as progress, but contrasts with a somewhat more skeptical view of science in Europe 
(McCluskey). 
Consumer concern about risks associated with the use of biotechnology in food production in 
Europe has led to a regulatory approach that rests much more heavily on the 'precautionary 
principle' (Barrett and Flora; and Ervin, et al.) . The precautionary principle is based on the 
premise that "when an activity raises threats of harm to human health or the environment, 
precautionary measures should be taken even if some cause-and-effect relationships are not yet 
fully established scientifically" (Barrett and Flora, p. 6). Whereas the U.S. approach tends to 
place the burden of proof on those who fear potential harm, the precautionary principle places 
the burden of proof primarily on proponents of biotechnology to demonstrate that there is, in 
fact, little or no risk of serious harm. Core elements of the precautionary principle include the 
following: 
• A primary goal of society is to protect the environment and public health. 
• Proactive measures should be taken toward this goal even in the face of scientific 
uncertainty. 
• The burden of demonstrating the safety of a potentially harmful technology falls on its 
developers, rather than on the public or government. 
• Alternatives must be considered. 
• Open, informed, and democratic processes must be used to make decisions about the 
acceptability of technology, its demonstrated safety, alternatives, research, and policy goals 
as well as the process to achieve these goals (Barrett and Flora, p. 7). 
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The European Union emphasizes the precautionary principle in its regulatory approach to 
biotechnology. This approach has been characterized as "guilty until proven innocent," while the 
U.S. approach has been called "innocent until proven guilty" (Ervin, et al., p. 37). Of course, 
there is a wide range of views about how to approach risk both within the United States and 
within Europe. There are many in the United States who advocate the precautionary principle, 
while there are sizeable numbers in Europe- particularly within the biological science 
community-who feel that the precautionary principle is too restrictive. These different 
approaches emphasize differences in val�es, both among cultures and among individuals within 
given cultures and societies. Science can not tell us which 'values' are correct. Consequently, 
though scientists may have their own, varying, opinions about an appropriate regulatory 
approach, they are in no position to dictate a philosophy of risk avoidance to the rest of society. 
Pretty ( 1999) has suggested a biotechnology regulatory approach based on six questions. 
When the answer to any of these questions appears to be 'no, ' then there is great need for caution 
and more research. If the answer appears to be 'yes,' then society is able to proceed with less 
caution. Pretty's ( 1999, p. 1 9) six questions are the following: 
• Does the biotechnology process only. involve gene transfers within the same or related 
species? 
• Is the biotechnology process fully contained (i.e. does the technology involve no release to 
the environment of genetically modified organisms)? 
• If the transgenic crops are released to the environment, will they affect only the target 
organisms as predicted? 
• Is the likelihood of food toxicity or antibiotic resistance effects in transgenic foods as low or 
lower than other foodstuffs? 
• Is the transgenic product fundamentally for the public good? Will it be distributed through 
public extension systems? 
• Are claims for environmental benefits arising from biotechnology use on the farm supported 
by practice? 
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These six questions, based substantially on the 'precautionary principle,' facilitate systematic 
thinking about the benefits and risks of biotechnologies. The framework helps to clarify that not 
all biotechnologies are the same. They vary in the types and magnitudes of potential benefits and 
risks offered. Consequently, policy and regulatory bodies that address these questions will lead 
to conclusions about research and commercialization of various biotechnology applications that 
are most appropriate to each application. 
Concluding Remarks 
There are rational reasons for people's suspicious attitudes towards new technologies. Hence, 
in democratic societies, public policies dealing with genetic modification technologies must 
incorporate concerns among citizens at all stages in the demand-supply chain. Such a system­
wide perspective allows one to view the multiple impacts and risks for different stakeholders in 
society. It also facilitates drawing upon the insights of various academic disciplines. Disciplines 
that are especially valuable for gaining policy insights about biotechnologies in a systems 
context are ecology, economics, and sociology. 
Contrary to a common belief among some non-economists, economics deals with much more 
than private, monetary benefits and costs. Economics is really about the implications of 
alternative resource allocation decisions. This includes both direct and indirect effects, as well as 
the effects that are measurable in monetary terms and those for which monetary measures are not 
readily available. Examples of effects that are highly relevant to systems oriented economic 
analyses, but which cannot always be measured monetarily, include many environmental or 
ecological impacts, as well as various social impacts. 
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The discussion on the merits and risks of agricultural biotechnology will require involving all 
participants in the food and fiber system, from agricultural producers to consumers of final 
products. Justification of biotechnology applications based on purely technical merits is a 
necessary condition for their successful implementation, but it is not sufficient. An additional 
requirement is that stakeholder concerns-including those of developing nations, environmental 
groups, and consumers-are addressed in an open and transparent manner. 
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Table 1. Global Area of Transgenic Crops, by Country, 1996-2000 (Million Hectares) 
2000* 
country 1996 1997 1998 1999 2000* (Percent) 
United States 1.5 8 .1 20.5 28 .7 30.3 70.5 
Argentina 0.1 1.4 4.3 6.7 8.8 20.5 
Canada 0.1 1.3 2.8 4.0 3.0 7 .0 
China <0.1 <0.1 0.3 0 .5 1 .2 
South Africa <0.1 <0.1 0.1 0.2 0.5 
Australia <0.1 0.1 0.1 0.2 0.5 
World 1.7 11.0 27.8 39.9 43 .0 100.2 
* Data for 2000 are based on preliminary estimates 
Source: James. 
Table 2. Genetically Modified Crops Grown in 2000, by Crop, 1996-2000 (Million Hectares) 
country 1996 1997 1998 
Soybeans 5.1 1 4. 5  
Corn 3 .2 8.3 
Cotton 1.4 2.5 
Cano la 1.2 2.4 
Other 0. 1 0.1 


















Table 3. Farmer Reported Genetically 
Modified Com Varieties, by State 
and for the United States, in Percent 
of All Planted Com Acres, 2001 
State % of Com Planted 











Other states 20 
United States 26 
Source: U.S. Department of Agriculture. 
27 
Table 4. Farmer Reported Genetically 
Modified Soybean Varieties, by 
State and United States, in Percent 
of All Planted Soybean Acres, 2001 
State % of Soybeans Planted 













North Dakota 49 
All Others 64 
United States 68 
Source: U.S. Department of Agriculture. 
Table 5 .  Farmer Reported Genetically 
Modified Upland Cotton Varieties, 
by State and for the United States, 
in Percent of All Planted Upland 
Cotton Acres, 2001 
Percent of 








Other states 84 
United States 69 
Source: U.S .  Department of Agriculture. 
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Figure 1 .  Schematic Overview of Perceptions o f  Benefits, Costs, and Risks ofBt Corn, by Different Segments of Society 
Benefits Costs Risks 
U.S .  Farmers Reduced production costs? Segregation costs. Access to markets. 
Loss of Bt spray effectiveness for 
organic farmers. 
Rest of the World Farmers Competition from lower cost 
imports. 
U.S .  Consumers Allergic reactions? 
Rest of the World Introduction to food chain over 
Consumers objections. 
Agribusiness Increased profits for the Higher costs to local elevators . Liability claims. 
patent holders. 
Environmentalists Reduced chemical use in the Continued lack of crop Toxic effects on some wildlife 
short run? biodiversity. species. 
U.S .  Taxpayers Increased monitoring costs. Buyout programs because of 
poor regulatory decisions. 
Rural Communities Increased concentration of 
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